BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on discovering and developing antibodies for oncological or inflammatory diseases. With the acquisition,
BioNTech to Acquire Biotheus for $800 Million to Expand Oncology Portfolio
BioNTech SE ( BNTX, Financials) announced plans to acquire Biotheus, a clinical-stage biotechnology company, for $800 million, securing full global rights to BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A.
Shares of vaccine makers, including Moderna (MRNA), BioNTech (BNTX), Pfizer (PFE), Novavax (NVAX), Vaxcyte (PCVX) and GSK (GSK) moved lower at the end of the trading day following reports that ...
Seeking Alpha on MSN1d
BioNTech to buy bispecific antibody developer Biotheus for up to $950MBioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX) will pay ...
The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Voyager Therapeutics (VYGR – Research ...
Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...
On Monday, BioNTech SE (NASDAQ:BNTX) reported third-quarter revenues of 1.244 billion euros (or $1.36 billion), up from 895.3 ...
BioNTech SE (BNTX) reports strong revenue growth and pipeline progress, while navigating financial and legal hurdles.
Shares of BioNTech (BNTX) gained in pre-market trading after the company reported better-than-expected Q3 earnings. The biotech company’s earnings increased by 22.7% to €0.81 ($0.89 ...
Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback